[go: up one dir, main page]

WO2015108490A3 - Heteroaryl alkyne derivatives and uses thereof - Google Patents

Heteroaryl alkyne derivatives and uses thereof Download PDF

Info

Publication number
WO2015108490A3
WO2015108490A3 PCT/SG2015/050005 SG2015050005W WO2015108490A3 WO 2015108490 A3 WO2015108490 A3 WO 2015108490A3 SG 2015050005 W SG2015050005 W SG 2015050005W WO 2015108490 A3 WO2015108490 A3 WO 2015108490A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
compounds
present
alkyne derivatives
heteroaryl alkyne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2015/050005
Other languages
French (fr)
Other versions
WO2015108490A2 (en
Inventor
Kassoum Nacro
Lohitha Rao Chennamaneni
Joseph Cherian
Anders Poulsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of WO2015108490A2 publication Critical patent/WO2015108490A2/en
Publication of WO2015108490A3 publication Critical patent/WO2015108490A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to certain heteroaryl alkyne compounds of Formula (I) that act as kinase inhibitors. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune disease, metabolic diseases, neurodegenerative diseases (e.g., Alzheimer's disease), or neurodevelopmental disorders (e.g., autism)), as well as methods of treating these diseases.
PCT/SG2015/050005 2014-01-17 2015-01-19 Heteroaryl alkyne derivatives and uses thereof Ceased WO2015108490A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1400787.6A GB2522226A (en) 2014-01-17 2014-01-17 Heteroaryl alkyne derivatives and uses thereof
GB1400787.6 2014-01-17

Publications (2)

Publication Number Publication Date
WO2015108490A2 WO2015108490A2 (en) 2015-07-23
WO2015108490A3 true WO2015108490A3 (en) 2015-11-26

Family

ID=50239082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2015/050005 Ceased WO2015108490A2 (en) 2014-01-17 2015-01-19 Heteroaryl alkyne derivatives and uses thereof

Country Status (2)

Country Link
GB (1) GB2522226A (en)
WO (1) WO2015108490A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US20170252350A1 (en) 2016-03-03 2017-09-07 Cornell University Small molecule ire1-alpha inhibitors
RU2652992C2 (en) * 2016-04-18 2018-05-04 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Novel crystalline salt form 3-(1,2,4-triazolo[4,3-a]pyridin-3-ylethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl) benzamide for medical application
JP7562256B2 (en) * 2016-08-15 2024-10-07 パデュー リサーチ ファウンデイション 4-Substituted Aminoisoquinoline Derivatives
CN108473476B (en) * 2016-10-13 2021-02-19 深圳市塔吉瑞生物医药有限公司 Alkynyl heterocyclic compounds for inhibiting protein kinase activity
CA3047106A1 (en) * 2016-12-15 2018-06-21 Ariad Pharmaceuticals, Inc. Aminothiazole compounds as c-kit inhibitors
MA53150A (en) * 2016-12-15 2021-05-26 Ariad Pharma Inc BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS
CN108456163A (en) * 2017-02-20 2018-08-28 中国科学院上海药物研究所 Compound and its preparation method and application containing adjacent amino heteroaryl cycloalkynyl radical
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
WO2019013703A1 (en) * 2017-07-14 2019-01-17 Agency For Science, Technology And Research (A*Star) Bicyclic alkyne derivatives and uses thereof
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
WO2020206583A1 (en) * 2019-04-08 2020-10-15 Qilu Regor Therapeutics Inc. Kinase inhibitors and uses thereof
AU2020304934A1 (en) * 2019-06-24 2022-01-20 Benevolentai Bio Limited New compounds and methods
EP4107155A4 (en) 2020-02-21 2024-04-03 Ascentage Pharma (Suzhou) Co., Ltd. A process for preparing alkynyl-containing compound and intermediate thereof
CN114075135B (en) * 2020-08-10 2024-06-11 上海润石医药科技有限公司 Salts of compounds containing o-aminopyridine alkynyl, and preparation method and application thereof
CN114163434B (en) * 2020-09-10 2023-05-23 苏州亚盛药业有限公司 Preparation method of alkynyl-containing compound and intermediate thereof
KR20220099503A (en) * 2021-01-05 2022-07-13 주식회사 비투에스바이오 Heteroaryl-ethynyl derivative compounds, and uses thereof
WO2022217821A1 (en) * 2021-04-13 2022-10-20 深圳市新樾生物科技有限公司 Alkynylphenylbenzamide compound and use thereof
CN116199688B (en) * 2021-11-23 2025-03-11 暨南大学 Cyclic compounds and their applications
EP4559909A1 (en) 2022-07-22 2025-05-28 Shenzhen Zhongge Biological Technology Co., Ltd. Compound for inhibiting irak4 activity and use thereof
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
WO2025165301A1 (en) * 2024-01-31 2025-08-07 National University Of Singapore Targeting metabolic pathways with mnk inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075869A2 (en) * 2005-12-23 2007-07-05 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
WO2012139027A1 (en) * 2011-04-07 2012-10-11 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
WO2013170774A1 (en) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 Acetylene derivative having antineoplastic activity
WO2014040549A1 (en) * 2012-09-17 2014-03-20 南京圣和药业有限公司 Alkynyl heteroaromatic ring compound and application thereof
WO2014082578A1 (en) * 2012-11-28 2014-06-05 南京圣和药业有限公司 Heteroaryl alkyne compound and application thereof
WO2014194667A1 (en) * 2013-06-05 2014-12-11 中国科学院上海药物研究所 Alkynyl heterocyclic compound and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101389338B (en) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 bicyclic heteroaryl compound
CN101490053B (en) * 2006-05-08 2013-09-11 阿里亚德医药股份有限公司 Monocyclic Heteroaryl Compounds
JP5273038B2 (en) * 2006-05-08 2013-08-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Monocyclic heteroaryl compound
MX2008014289A (en) * 2006-05-08 2008-11-26 Ariad Pharma Inc Acetylenic heteroaryl compounds.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075869A2 (en) * 2005-12-23 2007-07-05 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
WO2012139027A1 (en) * 2011-04-07 2012-10-11 Ariad Pharmaceuticals, Inc. Methods and compositions for treating neurodegenerative diseases
WO2013170774A1 (en) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 Acetylene derivative having antineoplastic activity
WO2013170770A1 (en) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 Acetylene derivatives having antitumor activity
WO2014040549A1 (en) * 2012-09-17 2014-03-20 南京圣和药业有限公司 Alkynyl heteroaromatic ring compound and application thereof
WO2014082578A1 (en) * 2012-11-28 2014-06-05 南京圣和药业有限公司 Heteroaryl alkyne compound and application thereof
WO2014194667A1 (en) * 2013-06-05 2014-12-11 中国科学院上海药物研究所 Alkynyl heterocyclic compound and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENG, X. ET AL.: "Broad spectrum alkynyl inhibitors of T315I Bcr-Abl", BIOORG. MED. CHEM. LETT., vol. 20, 2010, pages 4196 - 4200, XP029121028 *
DESAI, B. ET AL.: "Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening Platform", J. MED. CHEM., vol. 56, 2013, pages 3033 - 3047 *
HUANG, W.-S. ET AL.: "Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4- methyl-N- {4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl} benzamide ( AP 24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant", J. MED. CHEM., vol. 53, no. 12, 2010, pages 4701 - 4719, XP002615777 *
THOMAS, M. ET AL.: "Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant", BIOORG. MED. CHEM. LETT., vol. 21, 2011, pages 3743 - 3748, XP028387839 *

Also Published As

Publication number Publication date
WO2015108490A2 (en) 2015-07-23
GB201400787D0 (en) 2014-03-05
GB2522226A (en) 2015-07-22

Similar Documents

Publication Publication Date Title
WO2015108490A3 (en) Heteroaryl alkyne derivatives and uses thereof
ZA202401324B (en) Tyrosine kinase inhibitors
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
HK1214815A1 (en) Enhancer of zeste homolog 2 inhibitors
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
PH12016501307A1 (en) Compounds
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
MX369952B (en) Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1.
EP4464317A3 (en) Compounds and compositions and uses thereof
EA033236B1 (en) New pyrazole derivatives as nik inhibitors
GB2533454A (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2018003563A (en) New compounds.
WO2015033228A3 (en) Compounds and use for treating cancer
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX380290B (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
PH12019500198A1 (en) Compounds and compositions and uses thereof
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
WO2015001541A3 (en) Pharmaceutical film composition
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
MX2017002544A (en) Isoquinolinone derivatives useful in the treatment of cancer.
WO2015189830A9 (en) Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease
HK1237784A1 (en) Heterocyclic derivatives as rorgamma modulators

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15737845

Country of ref document: EP

Kind code of ref document: A2